Search research articles
Contact Us
Filters
Showing results (1-10 of 43) with videos related to
Page
of 5
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 29, 2002
Designing randomised trials: both large and small trials are needed
S P Stenning, M K B Parmar
British Journal of Cancer
|
October 10, 2002
First-line treatment for advanced ovarian cancer: paclitaxel, platinum and the evidence
J Sandercock, M K B Parmar, V Torri, et al.
Trials
|
April 21, 2009
How do multi-stage, multi-arm trials compare to the traditional two-arm parallel group design--a reanalysis of 4 trials
F M-S Barthel, M K B Parmar, P Royston
Clinical Oncology (Royal College of Radiologists (Great Britain))
|
October 29, 2017
Incorporating Biomarker Stratification into STAMPEDE: an Adaptive Multi-arm, Multi-stage Trial Platform
C Gilson, S Chowdhury, M K B Parmar, et al.
Statistics in Medicine
|
February 16, 2006
Evaluation of sample size and power for multi-arm survival trials allowing for non-uniform accrual, non-proportional hazards, loss to follow-up and cross-over
F M-S Barthel, A Babiker, P Royston, et al.
Journal of Clinical Epidemiology
|
March 18, 2011
A critical review of methods for the assessment of patient-level interactions in individual participant data meta-analysis of randomized trials, and guidance for practitioners
D J Fisher, A J Copas, J F Tierney, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
August 12, 2004
The European Canadian Intergroup trial (OV10 trial) and the US Gynaecologic Oncology Group trial (GOG 111)
A M C Swart, M K B Parmar, P Harper, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 17, 2007
Why i.p. therapy cannot yet be considered as a standard of care for the first-line treatment of ovarian cancer: a systematic review
A M C Swart, S Burdett, J Ledermann, et al.
Lancet (London, England)
|
December 17, 2008
Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study
, H Kitchener, A M C Swart, et al.
Lung Cancer (Amsterdam, Netherlands)
|
June 9, 2014
Interim results in clinical trials: do we need to keep all interim randomised clinical trial results confidential?
R J Stephens, R E Langley, P Mulvenna, et al.
Page
of 5
Search research articles
Search
Showing results (1-10 of 43) with videos related to
Sort By:
Page
of 5
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 29, 2002
Designing randomised trials: both large and small trials are needed
S P Stenning, M K B Parmar
British Journal of Cancer
|
October 10, 2002
First-line treatment for advanced ovarian cancer: paclitaxel, platinum and the evidence
J Sandercock, M K B Parmar, V Torri, et al.
Trials
|
April 21, 2009
How do multi-stage, multi-arm trials compare to the traditional two-arm parallel group design--a reanalysis of 4 trials
F M-S Barthel, M K B Parmar, P Royston
Clinical Oncology (Royal College of Radiologists (Great Britain))
|
October 29, 2017
Incorporating Biomarker Stratification into STAMPEDE: an Adaptive Multi-arm, Multi-stage Trial Platform
C Gilson, S Chowdhury, M K B Parmar, et al.
Statistics in Medicine
|
February 16, 2006
Evaluation of sample size and power for multi-arm survival trials allowing for non-uniform accrual, non-proportional hazards, loss to follow-up and cross-over
F M-S Barthel, A Babiker, P Royston, et al.
Journal of Clinical Epidemiology
|
March 18, 2011
A critical review of methods for the assessment of patient-level interactions in individual participant data meta-analysis of randomized trials, and guidance for practitioners
D J Fisher, A J Copas, J F Tierney, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
August 12, 2004
The European Canadian Intergroup trial (OV10 trial) and the US Gynaecologic Oncology Group trial (GOG 111)
A M C Swart, M K B Parmar, P Harper, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 17, 2007
Why i.p. therapy cannot yet be considered as a standard of care for the first-line treatment of ovarian cancer: a systematic review
A M C Swart, S Burdett, J Ledermann, et al.
Lancet (London, England)
|
December 17, 2008
Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study
, H Kitchener, A M C Swart, et al.
Lung Cancer (Amsterdam, Netherlands)
|
June 9, 2014
Interim results in clinical trials: do we need to keep all interim randomised clinical trial results confidential?
R J Stephens, R E Langley, P Mulvenna, et al.
Page
of 5